ROME Therapeutics Appoints Scientist and Entrepreneur Scott Biller, Ph.D. to Board of Directors

Dr. Biller Brings More Than 30 Years of Experience Discovering and Advancing Novel Molecules, Most Recently as Chief Scientific Officer at Agios Pharmaceuticals

CAMBRIDGE, Mass.--(BUSINESS WIRE)--ROME Therapeutics, a biotechnology company harnessing the power of the repeatome in drug development, today announced the appointment of Scott Biller, Ph.D., to the ROME Board of Directors. A chemist by training, Dr. Biller has more than three decades of experience in drug discovery and development, most recently as Chief Scientific Officer at Agios Pharmaceuticals. He has also held leadership positions at Novartis Pharmaceuticals and Bristol Myers Squibb.

“We are thrilled to add Scott’s unique insight as both a drug hunter and an entrepreneur to ROME’s diverse and experienced Board of Directors,” said Rosana Kapeller, M.D., Ph.D., CEO, President and Co-founder of ROME Therapeutics. “With his deep experience in drug discovery, development and company building, Scott will be a valued adviser as we advance ROME’s mission to harness the power of the repeatome to develop novel medicines.”

Dr. Biller currently serves as a strategic advisor to Agios Pharmaceuticals, after nearly a decade as the company’s Chief Scientific Officer. During his tenure as CSO, he advanced seven molecules into the clinic, leading to two marketed therapies and multiple late-stage candidates. He previously served as Vice President and Head of Global Discovery Chemistry at the Novartis Institutes for BioMedical Research and as Vice President, Pharmaceutical Candidate Optimization at the Bristol Myers Squibb Pharmaceutical Research Institute. During his career, Dr. Biller contributed to the discovery and development of five approved medicines: JUXTAPID® for familial hypercholesterolemia, ONGLYZA® and FARXIGA® for Type 2 diabetes, and IDHIFA® and TIBSOVO® for acute myeloid leukemia harboring an IDH2 and IDH1 mutation, respectively, as well as two new chemical entities that are currently in pivotal trials. He also serves as a member of the Scientific Advisory Board at Denali Therapeutics, and a member of the Board of Directors at Foghorn Therapeutics and Remix Therapeutics. Dr. Biller earned a B.S. in chemistry at MIT, a Ph.D. in organic chemistry at Caltech and was an NIH Postdoctoral Fellow at Columbia University.

“I was drawn to ROME’s unique biological hypothesis and implications for novel drug discovery in cancer and autoimmune diseases,” said Dr. Biller. “I am excited to work with the ROME team, external collaborators and the rest of the Board to translate this mission into a promising new class of medicines for patients.”

About ROME

ROME Therapeutics is developing novel therapies for cancer and autoimmune diseases by harnessing the power of the repeatome – vast stretches of uncharted genetic material that have long been dismissed as “junk DNA.” With several drug targets identified and multiple discovery programs underway, ROME is moving rapidly to leverage this new frontier in biology. To lead this exploration, ROME has assembled a team of world-class leaders across fields including oncology, immunology, virology and machine learning. ROME was launched in April 2020 and was incubated at GV, in collaboration with ARCH Venture Partners and Partners Innovation Fund. ROME is based in Cambridge, Mass. For more information, please visit www.rometx.com.

Media
Stephanie Simon
Ten Bridge Communications
617-581-9333
stephanie@tenbridgecommunications.com